HRTX earnings: next report 2026-08-14, real EPS beat/miss history, analyst consensus Buy, P/E -2.64. Updated 2026-07-23.
Heron Therapeutics (HRTX) Research Hub
Heron Therapeutics (HRTX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 0.3155 USD (-5.26%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -2.64, market cap 0.08B. This hub links to the full technical, earnings and options research available for HRTX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 0.3155 USD (-5.26%) |
| 52-week range | 0.3016 USD – 0.5399 USD |
| Trend regime | Range |
| 14-day RSI | 21.9 (Oversold) |
| Trailing P/E | -2.64 |
| Market cap | 0.08B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-14 |
Available research for HRTX
Covered Call on HRTX: how it works, illustrative setup around the real 0.3155 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on HRTX: how it works, illustrative setup around the real 0.3155 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on HRTX: how it works, illustrative setup around the real 0.3155 USD price, max profit/loss, breakeven and when to use it. Educational.
HRTX technical analysis: range, last 0.3155 USD, RSI 21.9, 52w range 0.3016 USD–0.5399 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is HRTX in?
Heron Therapeutics (HRTX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is HRTX in an uptrend or downtrend?
As of 2026-09-11, HRTX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is HRTX's trailing P/E ratio?
HRTX's trailing P/E is -2.64, with a market cap of 0.08B. See the earnings research page for full valuation detail.
When does HRTX next report earnings?
HRTX is next scheduled to report earnings on 2026-08-14, with a consensus EPS estimate of -0.02 USD.